Psychiatric Times
CONTINUE TO SITE

OR WAIT null SECS

Psychiatric Times
Spotlight
Commentary
Cultural Corner
Psychiatric Practice
Series
Topics
Media
Publications
Job BoardCME/CEPartners
Resources
Subscribe

  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Psychiatric Times. All rights reserved.

SpotlightSee All >
  • Bipolar I Disorder
  • (Sponsored) Taar1 Agonism: A Novel Approach to Treating Schizophrenia
  • Between the Lines: Narcolepsy
  • Case Reviews in Bipolar Disorder: Around The Practice
  • Major Depressive Disorder
  • Managing Patients With Treatment Resistant Depression
  • Perspectives in Insomnia
  • Sleep Disorders
CommentarySee All >
  • Couch In Crisis
  • Early Career Psychiatry
  • History of Psychiatry
  • Residents Corner
Cultural CornerSee All >
  • Film and Book Reviews
  • Poetry
  • Writers Contest
Psychiatric PracticeSee All >
  • Burnout
  • Careers
  • Coding
  • Guidelines
  • Risk Management
  • Telepsychiatry
SeriesSee All >
  • Climate Change
  • Critical Conversations in Psychiatry
  • Portraits
  • Psychiatric Views on the Daily News
  • Tales From the Clinic: The Art of Psychiatry
  • Tales from the New Asylum
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Psychiatric Times. All rights reserved.

EP 1: Phase 3 TRANSFORM Trial

October 21st 2021

Drs Harding and Halaris evaluate the phase 3 TRANSFORM trial that studied intranasal esketamine as a therapy option for treatment resistant depression.